These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY. Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691 [TBL] [Abstract][Full Text] [Related]
66. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Sadda SR; Tuomi LL; Ding B; Fung AE; Hopkins JJ Ophthalmology; 2018 Jun; 125(6):878-886. PubMed ID: 29477692 [TBL] [Abstract][Full Text] [Related]
67. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results. Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105 [TBL] [Abstract][Full Text] [Related]
68. Anti-VEGF therapy in a silicone oil-filled myopic eye with choroidal neovascularisation. Chhablani J; Narayanan R BMJ Case Rep; 2015 Apr; 2015():. PubMed ID: 25870215 [TBL] [Abstract][Full Text] [Related]
69. Subretinal injection of ranibizumab in advanced pediatric vasoproliferative disorders with total retinal detachments. Peng J; Liang T; Chen C; Zhang Q; Xu Y; Liu J; Zhao P Graefes Arch Clin Exp Ophthalmol; 2020 May; 258(5):1005-1012. PubMed ID: 32043167 [TBL] [Abstract][Full Text] [Related]
70. Risk factors for subretinal fibrosis after anti-VEGF treatment of myopic choroidal neovascularisation. Xiao H; Zhao X; Li S; Sun L; Xin W; Wang Z; Zhang A; Zhang J; Ding X Br J Ophthalmol; 2021 Jan; 105(1):103-108. PubMed ID: 32161005 [TBL] [Abstract][Full Text] [Related]
71. Spatial Correspondence Between Intraretinal Fluid, Subretinal Fluid, and Pigment Epithelial Detachment in Neovascular Age-Related Macular Degeneration. Klimscha S; Waldstein SM; Schlegl T; Bogunovic H; Sadeghipour A; Philip AM; Podkowinski D; Pablik E; Zhang L; Abramoff MD; Sonka M; Gerendas BS; Schmidt-Erfurth U Invest Ophthalmol Vis Sci; 2017 Aug; 58(10):4039-4048. PubMed ID: 28813577 [TBL] [Abstract][Full Text] [Related]
72. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration. Ach T; Hoeh AE; Ruppenstein M; Kretz FT; Dithmar S Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764 [TBL] [Abstract][Full Text] [Related]
73. Structural and optical coherence tomography angiography in myopic choroidal neovascularization: Agreement with conventional fluorescein angiography. Iacono P; Giorno P; Varano M; Parravano M Eur J Ophthalmol; 2021 Jan; 31(1):149-157. PubMed ID: 31619075 [TBL] [Abstract][Full Text] [Related]
74. Variable response of subretinal hyperreflective material to anti-vascular endothelial growth factor classified with optical coherence tomography angiography. Maruyama-Inoue M; Sato S; Yamane S; Kadonosono K Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2089-2096. PubMed ID: 30173338 [TBL] [Abstract][Full Text] [Related]
75. Choroidal nevus or melanoma? Choroidal neovascularisation as a confounder in choroidal nevus. Subira O; Brosa H; Lorenzo D; Caminal JM J Fr Ophtalmol; 2017 Jun; 40(6):531-534. PubMed ID: 28579218 [No Abstract] [Full Text] [Related]
76. Treatment of serous retinal detachment associated with choroidal ischemia with intravitreal bevacizumab following brain surgery. Cho YJ; Choi EY; Koh HJ; Lee SC; Kim M Korean J Ophthalmol; 2014 Oct; 28(5):424-6. PubMed ID: 25276086 [No Abstract] [Full Text] [Related]
77. Prediction of Anti-VEGF Treatment Requirements in Neovascular AMD Using a Machine Learning Approach. Bogunovic H; Waldstein SM; Schlegl T; Langs G; Sadeghipour A; Liu X; Gerendas BS; Osborne A; Schmidt-Erfurth U Invest Ophthalmol Vis Sci; 2017 Jun; 58(7):3240-3248. PubMed ID: 28660277 [TBL] [Abstract][Full Text] [Related]
78. Rescue therapy with intravitreal aflibercept for choroidal neovascularization secondary to choroidal osteoma non-responder to intravitreal bevacizumab and ranibizumab. Saitta A; Nicolai M; Neri P; Reibaldi M; Giovannini A; Mariotti C Int Ophthalmol; 2015 Jun; 35(3):441-4. PubMed ID: 25761547 [TBL] [Abstract][Full Text] [Related]